Recurrent Venous Thromboembolism
Low-dose apixaban for extended anticoagulation may be option for preventing cancer-related VTE
CHICAGO — For patients with cancer requiring extended anticoagulant therapy, a strategy of reduced-dose apixaban was noninferior to full-dose apixaban for prevention of cancer-associated recurrent venous thromboembolism.
Top in hem/onc: Hydroxychloroquine and cancer, racial disparities in care
New data showed that hydroxychloroquine combined with other COVID-19 treatments may increase the risk for mortality among patients with cancer. It was the top story in hematology/oncology last week.
New VTE incidence ‘significant’ after CAR T-cell therapy for lymphoma
ORLANDO — More than one in 10 patients with lymphoma who underwent chimeric antigen receptor T-cell therapy developed new venous thromboembolism, according to study results presented at TCT | Transplantation & Cellular Therapy Meetings.
Extended edoxaban, dalteparin equally effective among patients with cancer, venous thromboembolism
Extended treatment with oral edoxaban appeared comparable to subcutaneous dalteparin in safety and effectiveness for prevention of recurrent venous thromboembolism and major bleeding among patients with active cancer, according to results of a post-hoc analysis published in Journal of Thrombosis and Haemostasis.